Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advaxis Immunotherapy Boosts 12-Month Survival In Cervical Cancer

This article was originally published in Scrip

Executive Summary

Advaxis Inc. reported that 38.5% of advanced cervical cancer patients – a group that normally survives for four to seven months on average – survived for at least 12 months after treatment with the company's immunotherapy axalimogene filolisbac (ADXS-HPV) in the first stage of a 67-patient, investigator-initiated, two-stage Phase II clinical trial.

You may also be interested in...



Advaxis Zips Listeria/Opdivo Combo Straight To Registrational Cervical Cancer Trial

Potentially registrational trial of ADXS-DUAL Listeria-based vaccine with Bristol's PD-1 inhibitor Opdivo in recurrent metastatic cervical cancer will complement Advaxis's adjuvant study of earlier-generation candidate axalimogene filolisbac.

Advaxis Advances Personalized Cancer Vaccines With Eye On Manufacturing Time, Cost

Advaxis is developing – now with help from partner Amgen – a personalized immunotherapy strategy with each patient's cancer vaccine based on their own tumor's specific neoepitopes.

Amgen Lays Out Plans For Rare Disease Portfolio Growth

Amgen detailed plans for increasing sales of drugs acquired in its Horizon transaction and outlined growth opportunities in its R&D pipeline during a rare disease showcase. 

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC029793

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel